Antitumor efficacy of cytokine-armed adenoviruses combined with adoptive T-cell transfer. B16-OVA tumor-bearing C57BL/6 mice were administered 1.5 × 106 CD8-enriched OT-I T-cells intraperitoneally on Day 1 with concurrent intratumoral injections of 1 × 109 viral particles of adenoviruses armed with (a) mIL2, (b) mTNFα, (c) mIFNg, and (d) mIFNb. Virus treatments continued every 7 days. Error bars, mean + SEM, n = 5–6. *P < 0.05, **P < 0.01, ***P < 0.001.